CN1953733A - Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GnRH - Google Patents

Abstract

Polymeric devices for controlled release of an active agent of interest are provided. The active agent is provided within a biodegradable polymer system to supply a polymeric device for controlled release of the active agent. The polymer system is a copolymer or a polymer blend comprising a hydrophobic component and a hydrophilic component, and the polymer system does not form a hydrogel when contacted with, or immersed in an aqueous system, for example when the device is implanted in a subject. When the device is administered to a subject, for example, when it is implanted, the device releases the active agent in a controlled fashion without a lag period, or with a minimal lag period. Methods for producing the polymeric devices are also provided, as are methods of using the polymeric devices to provide for controlled release of an active agent in a subject. Preferred hydrophobic component is a PLG. Preferred hydrophilic Components are a PEG or a methoxyPEG. Preferred peptides are LHRH, goserelin, leuprolide.

Description

Be used for the polymeric implants of the mixture that preferably contains PEG and PLG that sustained release is preferably the activating agent of GnRH

Technical field

The present invention belongs to the field that is used to carry such as the sustained release device of peptide or the agent of the biological medicine isoreactivity of protein substantially, wherein, needs the lag period minimum or do not have homogeneous, zero level or the linear release kinetics of lag period.

Background technology

In the art, the biodegradability Controlled Release System that is used for activating agent is known.The biodegradability substrate that is used for drug conveying is very useful, and this is because they do not need to remove device after the drug depletion.

The modal host material that is used for Controlled Release System is a polymer.Reported that since (Arch.Surg., 93:839,1966) such as Kulkarni the development of biodegradability polymer arts is very fast after the synthetic and biological degradability of polylactic acid.The example of having reported other polymer of the host material that can be used as Controlled Release System comprises polymer and copolymer, the end capped poly(ethylene oxide) of acrylic acid, polyamide, polyurethane, poe, polyacrylonitrile and the polyphosphazene of polyanhydride, polyester (as poly-Acetic acid, hydroxy-, bimol. cyclic ester and polylactide-co-glycolide), polyamino acid (as polylysine), poly(ethylene oxide).For example see the United States Patent (USP) 4 of authorizing Langer, 891,225 and 4,906,474 (polyanhydrides), authorize the United States Patent (USP) 4 of Hutchinson, 767,628 (polylactides, polylactide-co-glycolide acid), authorize the United States Patent (USP) 4 of Tice etc., 530,840 (polylactides (polylactide), poly-Acetic acid, hydroxy-, bimol. cyclic ester and copolymer), and United States Patent (USP) 5,234,520 (Dunn etc. are used to control the biodegradability polymer (biodegradable polymers for controlled delivery intreating periodontal disease) of conveying in the periodontal disease in treatment).

The degradability material of biogenetic derivation is known already, comprises for example crosslinked gelatin.Hyaluronic acid has obtained crosslinked, and be used as the bio-pharmaceutical applicator the degradability expanded polymer (for example see United States Patent (USP) 4,957,744 and Della Valle etc. (1991), Polym.Mater.Sci.Eng., 62:731-735).

The biodegradability hydrogel also is developed for Controlled Release System also as the carrier such as bioactive substances such as hormone, enzyme, antibiotic, antitumor agent and cell suspension agent.For example see the United States Patent (USP) 5,149,543 of authorizing Cohen.

The solid phase material of hydrogel composition during also impression material, wound dressing material and the size exclusion chromatography of the substrate through being commonly used for cell and tissue culture, prosthodontics or affinity chromatography are used.For example, non-porous, deformation and/or deutero-agarose aquogel compositions has been used in (Li etc. (1990) in high performance liquid chromatography and the affinity chromatography, Preparative Biochem.20:107-121), and super permeability agarose aquogel pearl has been used as the holder (Gustavsson etc. (1999) in the hydrophobic interaction chromatography, J.Chromatography, 830:275-284).

In pharmaceutical field, usually hydrogel monomer (natural or synthetic) is added in the pharmaceutical composition (contain initiator, and contain cross-linking agent sometimes), carry out polymerization then, thus with the object drug encapsulation in hydrogel matrix.Hydrogel macromonomer through suitably selecting can form the film that is applicable to the permeability with certain limit, aperture and degradation rate in various operations, medical diagnosis and the treatment application.These technology are used to provide the microsphere carrier system that is used for drug targeting or Controlled Release System.For example, the cross-linked hydrogel microsphere has been used to seal the islet cells (Lim etc. (1980) that are used for the treatment of diabetes, Science, 210:908-910) or be used for sealing the cancerous cell (United States Patent (USP) 5,888,497) that can produce cancerocidal substance, and biodegradability hydrogel microsphere body is widely used for sealing various pharmaceutical compositions, modal be used for sealing peptide and protein (Wang etc. (1997), Pharm.Dev.and Technology, 2:135-142).In these were used, the specific aquogel system of selecting to use in the preparation came long-term embedding object cell or pharmaceutical substances (for example, the pharmacokinetics that targeted is provided or continues or postpone to discharge).Perhaps, in the ampholyte copolymer system, adopt hydrogel as hydrophilic component.In this case, the content of hydrogel is relatively large, makes this polymeric system can absorb a large amount of water.For example see the United States Patent (USP) 4,526,938 and 4,942 of authorizing Churchill etc., 035.

Summary of the invention

The invention provides the polymeric device that is used for the sustained release active agent of interest.This device comprises the biodegradability polymeric system with the activating agent combination, and this polymeric system is selected from copolymer and the polymer blend (polymeric blend) that comprises hydrophobic components and hydrophilic component.Described polymeric acceptor ties up to and does not form hydrogel when described device contacts with water-based system.In addition, described device does not have the lag period or has the shortest lag period when discharging described reagent.By this way, polymeric device of the present invention is for the usefulness of zero level or Linear Control release bioactive agent.

The present invention also provides the biodegradability polymeric acceptor to tie up to the purposes of making the polymeric device that is used for the sustained release active agent of interest.Described biodegradability polymeric system is selected from copolymer and the polymer blend that contains hydrophobic components and hydrophilic component, and makes up to form described device with activating agent.Described polymeric acceptor ties up to and does not form hydrogel when described device contacts with water-based system.Do not have the lag period when in addition, this device discharges described reagent or have the shortest lag period.By this way, polymeric device of the present invention is for the usefulness of zero level or Linear Control release bioactive agent.

The content that is present in the activating agent in the described device can be up to about 40 weight % or more than the 40 weight %.In some embodiments, activating agent is peptide therapeutics and/or preventive.For example, therapeutic peptide and/or preventative peptide can be selected from hormone, somatomedin, neural activity agent, melanotropin peptide (melanotropic peptide), the cell adhesion factor, cytokine and biological response modifier.One preferred embodiment in, described activating agent is GnRH molecule or GnRH analog.Some preferred embodiment in, the GnRH analog can be selected from ground Suo Ruilin (desorelin), color ammonia Rayleigh (tryptorelin), goserelin and leuproside.

In practice of the present invention, hydrophobic polymer component and hydrophilic polymer or monomer copolymerization most preferably are block copolymer to obtain copolymer systems; Perhaps mix with hydrophilic polymer to obtain blended polymeric system.The feature of these polymeric systems of gained is to have a spot of hydrophilic nmature, but they do not form hydrogel after in being immersed in water-based system.For example, the preferred polymeric system that uses in the compositions of the present invention can comprise its amount and be generally the water-soluble polymer of 25 weight %～30 weight % (as Polyethylene Glycol (PEG)) at the most, it does not give the hydrogel character that arrives seen in the former sustained release device, but still forms and show single-phase or zero level or near the device of the release dynamics of zero level.If use PEG in this system, the preferred molecular weight of PEG can be about 700Da～about 500kDa.Particularly preferred other hydrophilic polymeric objects system that uses in polymeric system of the present invention comprises polyvinylpyrrolidone, polyvinyl alcohol, poly-(alkylene amines) and poly-(alkylene oxide).

In some embodiments, the content of hydrophilic component is at most 25%.In other embodiment, the content of hydrophilic component is at most 15%, and perhaps content is 0.5 weight %～10 weight %.In other some embodiment, described polymeric system comprises the hydrophobic polymer that surpasses 75 weight %.In other embodiment, described polymeric system comprises the hydrophobic polymer that surpasses 85 weight %, surpasses the hydrophobic polymer of 91 weight %, or even surpasses the hydrophobic polymer of 98 weight %.

One preferred embodiment in, the hydrophobic components of described polymeric system is selected from such as poly-(lactide), poly-(Acetic acid, hydroxy-, bimol. cyclic ester), poly-(lactide-co-glycolide), poly-(lactic acid), poly-(glycolic) and polyhydroxy acid, polyanhydride, poe, polyether ester, polycaprolactone, polyesteramides such as poly-(lactic acid-altogether-glycolic), gathers phosphazine, Merlon, polyamide and their copolymer.Another preferred embodiment in, described polymeric acceptor is the AB copolymer, wherein the A component is the copolymer of lactide, Acetic acid, hydroxy-, bimol. cyclic ester or caprolactone, and the B component is a poly alkylene glycol.In a particularly preferred embodiment, the B component is the poly alkylene glycol of 1.25 weight %, and hydrophobic polymer is poly-(lactide-co-glycolide).

In any device of the present invention, activating agent can be evenly distributed in the polymer.Described device can use non-solvent method that activating agent is joined in the polymeric system and form.In addition, described device can melt extrude by the dry type of copolymer or melt extrude and forms.One preferred embodiment in, can need not to use solvent and adopt two extrusion steps to make described device to guarantee the maximum dispersion degree of activating agent in polymer.The hydrophilic component of polymer is to help moisture absorption but be lower than the amount that can cause hydrogel to form and exist, and this amount is generally 25 weight % less than polymer.The addition of activating agent is at most 40 weight %, but this amount can be higher, preferably in the situation of peptide.

Device of the present invention can provide with any suitable form, and this depends on the method for application of this device.In this, apparatus of the present invention can administered by oral route (such as capsules such as hard capsule and soft capsules, such as granule, tablet, pill, lozenge or lozenge, cachet, pilule, powder, granule, solid preparations such as microgranule (and any other particulate form)) and non-oral route (for example, intramuscular, subcutaneous, transdermal, internal organs, IV (intravenous), IP (intraperitoneal), intra-arterial, in the film sheath, in the capsule, in the eye socket, ophthalmic, in the tumor, around the blood vessel, intracranial, near the eyes, in the eyelid, intranasal, in the hole, intravesical, intravaginal, in the urethra, internal rectum, adventitia, injectable, pulmonary, can suck, see through mucosa with other suitable form).

One preferred embodiment in, described device is used by implantation, thereby be configured to moulded products, for example spherical, rod shape, tabular, membranaceous, fibrous, needle-like, cylindric, lamellar, tubulose or comprise any other suitable geometry of microgranule, microsphere and/or microcapsule.Can provide described device to be used for privileged sites with any appropriate size of implantable device and shape, conduit for example, diverter, the device that is used for continous pouring under the arachnoidea, feeding tube, prevent the solid implant of surgical adhesions, the uterus implant, artificial sphincter, the all implants of urethra, clamping plate, ocular implants, contact lens, the plasticity surgery implant, comprise esophageal stents appear, gastrointestinal tract support, intravascular stent, biliary tract rack, the colon support, the pancreas support, ureter bracket, urethra rack, lacrimal stent, the pharyngotympanic tube support, method Lou skin Europe support (fallopian stent), nose stretcher, the hole support, support such as trachea bracket or bronchial stent (contain or be coated with activating agent), or comprise the venous access device, the property implanted passage, epidural catheter or centre pipe passages such as (PICC).

Described device can or use trocar, conduit etc. to be implanted to desired area by the technology of invasive minimum by operation.Therefore, this implant can be used such as routine techniquess such as (for example in intra-arterial, intravenous, intravaginal, internal rectum or the periodontal cavity) implantation in Intradermal, subcutaneous, percutaneous, intraperitoneal, intramuscular or the tube chamber and be implanted in any suitable tissue.Perhaps, described device can be made the part of substrate, graft, prosthesis or coating.If implantable device is made into such as microgranule, microsphere or microcapsule equigranular thing form, then can use apparatuses such as sleeve pipe, pin and syringe to inject the suspension of described shot-like particle and it is implanted in the suitable tissue.

In the method for the invention, described device can be used by any suitable method.According to the position that activating agent to be applied, selected form (size, shape etc.) and selection are used, carry or implant at the position that will discharge with the method for invasive minimum.These methods can comprise and use implantation that trocar or conduit carried out, use conventional needle and syringe injection, immigration or operation or nonoperative arrangement (for example substrate, graft, prosthesis or coating are used) that (for example powder, granule, microgranule, microsphere and microcapsules) carried out, suck (for example powder or shot-like particle are used) etc.Described device is designed so that activating agent discharges with required dosage in the time of determining.With described device be designed so that its in the activating agent dispose procedure or finish discharge after degraded.

In a preferable methods, described device is mixed with in the solid implant form, comprises GnRH molecule or GnRH analog.Then described device is applied to the experimenter, so that experimenter's promoting sexual gland hormone (LH or FSH) reaches certain target blood levels, output, function or activity.

Description of drawings

Fig. 1 is at 37 ℃, and mPEG-5000-DL-PLG (90: the 10) water of measuring when hydration increases in time absorbs and expansible figure.

Fig. 2 be peptide in time from the cumulative release of the device of various sizes and the figure of rate of release, described device is with the acetic acid leuproside preparation of 30 weight % (wt%) in mPEG-750 DL-PLG (90: the 10) block copolymer.

Fig. 3 is the figure of the influence of the release in vitro of plant bulk Dichlorodiphenyl Acetate leuproside (" LA ") from device, and described device contains the LA of 30 weight % in mPEG-5K DL-PLG (90: 10) block copolymer.

The specific embodiment

Before describing the present invention, should be appreciated that the present invention is not particularly limited in polymeric system of being enumerated or machined parameters, this is because polymeric system or the method parameter enumerated obviously can change.And the purpose that be also to be understood that term used herein is just in order to describe the specific embodiment of the present invention, rather than will limit the present invention.

Must be pointed out that, unless make clear and definite different indication in the literary composition, used singulative " " in this description and the appending claims, " a kind of " and " this or this " comprise the object of a plurality of (or kind) indication.Therefore, for example when referring to " a kind of hydrophobic polymer ", it comprises two or more described mixture of polymers, and when referring to " a kind of reagent " or " a kind of activating agent ", it comprises the mixture of two or more described material, or the like.

An object of the present invention is to provide a kind of biodegradable sustained release device, it discharged such as the agent of medicine isoreactivity in the time that prolongs, and more controlled zero level or linear release kinetics are provided, rather than biphase release dynamics.

Another object of the present invention provides the manufacture method of described device, and this method saves cost, be highly repeatably, effectively and use minimum solvent (if you are using).

Developed a small amount of hydrophilic polymer has been joined compositions and method in the device, described compositions and method make such as peptide or the agent of pharmaceutical grade protein isoreactivity and can discharge from the monoblock type compositions with the biodegradable hydrophobic polymer of hydrolyzable (for example poly-(DL-lactide-co-glycolide), i.e. DL-PLG) preparation with more stable or linear speed.Hydrophobic polymers such as use such as PLG also are added with and a spot ofly provide particularly advantageous release profiles such as poly-(ethylene glycol) hydrophilic polymers (this hydrophilic polymer preferably covalently is connected on the main chain of described hydrophobic polymer) such as (being PEG).In addition, with selected material with comprise that dry type is for example mixed, compound (once by extruding), grind and heavily extrude etc. simple method combination can be further for the usefulness of favourable release profiles.Described monoblock type compositions or device can be the goods of Any shape, described shape is for example spherical, cylindric, lamellar or comprise other geometry of microgranule, microsphere and/or microcapsule, and described monoblock type compositions or device comprise the mixture such as the hydrophobic polymer that is added with a small amount of hydrophilic polymer of medicines such as peptide and copolymer form or blend.Preferred manufacture method avoids using solvent to come mixed polymer and medicine.

Described device can be designed to provide single-phase release, that is, release is generally linearity or zero level, but can comprise the minimum or non-existent continuous release of wherein initial " burst release " or " hysteresis " effect.

The technical staff is faced with numerous and the problem of carrying for a long time such as biologically active polypeptides such as polypeptide hormones from the implantable induction system of biodegradability.Because peptide is normally insoluble in such as DL-polylactide-co-glycolide hydrophobic polymers such as (" DL-PLG "), therefore the solid composite that comprises the mixture of peptide and DL-PLG generally provides as biphase, and wherein component (for example peptide) is present in a large amount of components (for example DL-PLG) as decentralized photo in a small amount.And because the glassy state character of DL-PLG, these materials are not to be easy to see through for having peptide molecule, especially those water soluble molecules of size like that usually.As a result, utilize the simple diffusion of passing polymeric matrix can't occur the release of peptide from DL-PLG usually.On the contrary, the appearance of release is owing to passing the diffusion that formed aqueous passage carries out when solid composite is placed in the aqueous environments.

When the polymeric compositions with prior art placed aqueous environments, water can be absorbed and make dispersive peptide dissolving, causes being dispersed with in the polymeric matrix the high aqueous solution zone of peptide concentration.The peptide that contacts with dosage surface can be owing to spread to pass because of the formed aqueous passage of the hydration of polymer and discharge.Because the diffusion distance is short and resistance is little, this almost is instantaneous generation.Yet when the peptide carrying capacity in the DL-PLG substrate was relatively low, owing to be not diffused into surperficial passage away from the peptide on surface, therefore in a single day the peptide with surface combination exhausted, and discharged and can end or rapid decline.Along with the carrying out of degraded, the increase of hydroxyl and carboxylic acid end group can cause the hydrophilic of substrate to strengthen gradually then.Along with the increase of water supply in media content, can form new aqueous passage, thereby for more away from peptide the approach that passes through is provided, make described peptide can be spread to the surface and be released.The release profiles of gained often presents two phasic properties, and wherein two release stages are had little or no therebetween and stage that peptide discharges take place separately." stagnation " stage between two release stages of appearing at, the purpose of described agonist was to continue to suppress such as lutropin promoting sexual gland hormone such as (" LH ") for especially thorny such as numerous peptides such as gonadotropin releasing hormone (" GnRH ") agonist.

Make " stagnation " stage method minimum or that eliminate comprise the peptide content that improves in the compositions.Owing to increased the peptide content in the compositions, strengthened between the particle between the peptide particle contacting, thereby pore network more widely is provided, and the peptide ratio that discharges in the starting stage is increased, if it does not finally comprise all medicines in the compositions, but also comprise most medicine.Discharge and follow the known Higuchi model that from the dispersion medicine unitary device, discharges usually, and show as " square root of time " kinetics.

Lag phase another method minimum and drug release that realization is more stable is comprised use degraded polymer composition relatively rapidly.For example, authorize the United States Patent (USP) 4 of Hutchinson, 767,628,5,004,602,5,366,734 have described the compositions of lasting release, wherein by to the monomer ratio of DL-PLG and the meticulous selection of molecular weight, the initial propagations control stage of release and the second degraded control stage of release are overlapped.This technical description mix have that different monomers is formed and molecular weight two or more excipient and realize required release profiles.The method of making described implant system relates in glacial acetic acid carries out solvent to peptide and one or more excipient, and this mixture of lyophilizing to be removing acetic acid, and molding or extrude this freeze-dried composition is to form implant.

The another one method comprises uses the biodegradability hydrogel that the permeability of peptide in polymeric matrix is significantly improved.For example, authorize the United States Patent (USP) 4 of Churchill, 526,938 and 4,942,035 has described sustained-release composition, and said composition comprises pharmaceutically active peptides and amphiphilic block copolymer, and wherein hydrophobic components has biodegradability and hydrophilic component can have or do not have biodegradability.Usually, these compositionss contain the hydrophilic component of relatively large amount, thereby make resulting polymer become the hydrogel that can absorb large quantity of moisture.For example, comprising 25 parts of PEG and 75 parts of intrinsic viscositys is the polymer of 0.41dL/g poly-(DL-lactide), when being pressed into the thin film of 0.2mm, 37 ℃ in water with absorbing himself weight moisture in 24 hours.Churchill etc. have described by the implant of same polymer preparation of compositions and by the implant of the block copolymer preparation of the DL-PL of PEG-6000 that comprises 5 weight % and 95 weight %.Described implant contains the goserelin acetate of 23.8 weight %.Goserelin continues the higher implant to discharge about 18 days from hydrophilic from these systems external, continues to discharge above 250 days from the lower implant of hydrophilic.These compositionss can also utilize glacial acetic acid that peptide and polymer are carried out solvent, prepare by lyophilizing then.

The United States Patent (USP) 6,159,490 of authorizing Deghenghi has been described and has been used for making peptide to carry the preparation method of implant of 1～12 month time from the copolymer of lactide and Acetic acid, hydroxy-, bimol. cyclic ester.The method of Deghenghi comprises the immixture that at first prepares peptide and polymer by following steps: (1) grinds polymer; (2) will make up through the polymer of grinding and the water paste of peptide; (3) this mixture being carried out drying anhydrates to remove.Then, melt extrude this mixture at 70 ℃～110 ℃.The United States Patent (USP) 6,217,893 of authorizing Pellet etc. has been described and is provided peptide from the polymer of lactide and Acetic acid, hydroxy-, bimol. cyclic ester or the compositions of the lasting release the copolymer, and described polymer or copolymer are at CHCl ₃In intrinsic viscosity be 0.5dL/g～1.6dL/g, and have water-wet behavior.Water-wet behavior is defined as the polymer with polar chain end, but also is defined as those acid numbers for more than or equal to 1, is preferably 1.5～2 polymer.Pellet also illustrates the peptide that need have high-specific surface area.But do not provide the embodiment of preparation implant or the embodiment that from implant, discharges.

The described method of Hutchinson and Churchill utilizes glacial acetic acid to come mixed polymer and medicine as solvent.In the United States Patent (USP) 6,159,490 of authorizing Deghenghi, described other aqueous methods and be used for peptide is carried 1～12 month time from the copolymer of lactide and Acetic acid, hydroxy-, bimol. cyclic ester implant with preparation.The method of Deghenghi comprises the immixture that at first prepares peptide and polymer by following steps: (1) grinds this polymer; (2) will make up through the polymer of grinding and the water paste of peptide; (3) this mixture being carried out drying anhydrates to remove.Then, melt extrude this mixture at 70 ℃～110 ℃.

These methods of eliminating " stagnation " stage that discharges of past comprise that needs mix two kinds of different polymer, needs expand and form the polymer of hydrogel or need have the polymer that contain sour functional end group or other hydrophilic end group more.The mixing of two kinds of polymer need and be carried out all steps and provide preparation for other procedure of processing in making with two kinds of material layouts.PLG adds the PEG that is enough to placing the aqueous environments back to form hydrogel and will expand significantly, and might be inhomogeneous.Because the carbinol-functional that per molecule has only a sour end group usually and evenly exists, the polymer that therefore has the sour end group of more amount can only change in very little scope.With regard to manufacture method, all above examples all relate to an organic solvent or water carries out the solvent of some type.What this can cause the dissolvent residual that can have a negative impact to polymer or experimenter may.In addition, the solvent step may cause medicine or compositions degraded, and has the consequence of increase time and cost.

To be suitable for these identical considerations equally for non-peptide reagent.

I. material and composition

A. polymeric system

Can be with method disclosed herein by various polymer formation devices with biocompatibility and biodegradability.Biodegradability as herein defined, is meant polymer degradation in vivo or ablation and forms less chemical substance, and wherein degraded can be because for example enzymatic, chemistry and physical process cause.In most preferred embodiments, polymer is hydrophobic substantially and degrades by hydrolysis.Term used herein " biodegradability " is meant does not have significantly infringement or the polymer of adverse effect and any catabolite of this polymer to the receptor health.

Be applicable to that the biodegradability polymer of the compositions and methods of the invention and the example of oligomer include but not limited to: poly-(lactide); Poly-(Acetic acid, hydroxy-, bimol. cyclic ester); Poly-(lactide-co-glycolide); Poly-(lactic acid); Poly-(glycolic); With poly-(lactic acid-be total to-glycolic); Poly-(caprolactone); Poly-(malic acid); Polyamide; Polyanhydride; Polyamino acid; Poe; Polyether ester; Polybutylcyanoacrylate; Poly-phosphazine; Poly-phosphide; Polyesteramide; The Ju diethyleno dioxide ketone; Poly-acetal; Polyketals; Merlon; Poly-orthocarbonic ester; Degradable polyurethane; Poly butyric ester; Poly-hydroxyl valerate; The polyalkylene oxalate; The polyalkylene succinate; Chitin; Chitan; Oxidized cellulose; And the copolymer of above any material, ter-polymers, blend, combination or mixture.

" hydrophobic " used herein is meant water-insoluble polymer basically." hydrophilic " used herein is meant water-soluble polymer or refers to have suction affinity but do not have the suction affinity when being covalently bound on the hydrophobic components as co-polymer usually, and can attract the polymer in the water access to plant.

Being fit to hydrophilic polymer used herein can be obtained by various commercially available, natural or synthetic source known in the art.Suitable hydrophilic polymer includes but not limited to: the polyanion class comprises anion polysaccharide (as alginate); Agarose; Heparin; Polyacrylate; Poly-methyl acrylate; Ethylidene maleic anhydride copolymers (half ester); Carboxy methyl amylose; Carboxymethyl cellulose; Sensor Chip CM 5; Carboxymethyl starch; Carboxymethyl chitin/chitan; Carboxycellulose; 2, the 3-dicarboxylcellulose; Three carboxyl celluloses; The carboxyl Radix Acaciae senegalis; The carboxyl chondrus ocellatus Holmes polysaccharide; Carboxyl pectin; The carboxyl Tragacanth; The carboxyl xanthan gum; The carboxyl guar gum; Carboxyl starch; Poly-sulphuric acid pentosan; Curdlan; Six sulphuric acid inositols; The sulphuric acid beta-schardinger dextrin-; Hyaluronic acid; Chrondroitin-6-sulfate; Dermatan sulfate; Dextran sulfate; Heparin sulfate; Chondrus ocellatus Holmes polysaccharide; Polygalacturonic acid; Polyphosphate; Polyacetals base carbonic acid; Poly--1-hydroxyl-1-sulfonic acid-propylene-2; The co polystyrene maleic acid; Meso polysaccharide (mesoglycan); Sulfo group propylated polyvinyl alcohol; Sulfate cellulose; Protamine sulfate; The phosphoric acid guar gum; Polyglutamic acid; Poly-aspartate; Polyamino acid; And their any derivant or combination.It should be appreciated by those skilled in the art that and also include other hydrophilic polymer within the scope of the invention.

Being fit to various water-soluble polymers used herein includes but not limited to: poly-(aklylene glycol), Polyethylene Glycol (" PEG "); Propylene glycol; Ethylene glycol/propylene glycol copolymers; Carboxymethyl cellulose; Glucosan; Polyvinyl alcohol (" PVOH "); Polyvinylpyrrolidone; Poly-(alkylene amines); Poly-(alkylene oxide); Gather-1, the 3-dioxolanes; Gather-1,3, the 6-trioxane; Ethylene/maleic anhydride copolymers; Polyamino acid; Poly-(positive vinylpyrrolidone); Poly(propylene oxide)/ethylene oxide copolymer; Polyoxy ethylization polyhydric alcohol; The polyvinyl alcohol succinate; Glycerol; Oxirane; Expoxy propane; Poloxamer; The alkoxylate copolymer; Water soluble polyanion; And their derivant or combinations arbitrarily.In addition, water-soluble polymer can have suitable molecular weight arbitrarily, can be side chain or non-side chain.

In practice of the present invention, hydrophobic polymer component and hydrophilic polymer or monomer copolymerization most preferably are block copolymer to obtain polymeric system, perhaps mix with hydrophilic polymer to obtain blended polymeric system.These polymeric systems of gained are characterised in that to have a spot of water-wet behavior, but they do not form hydrogel after in being immersed into water-based system.For example, in compositions of the present invention the preferred polymeric system that uses can comprise its amount usually at the most 25 weight %～30 weight % such as Polyethylene Glycol water-soluble polymers such as (PEG), this polymeric system is not given Churchill described hydrogel character, shows single-phase or zero level or near the device of zero level release dynamics but form.If use PEG in this system, its preferred molecular weight can be about 700Da～500kDa.Other preferred especially hydrophilic polymer that uses in polymeric system of the present invention comprises polyvinylpyrrolidone, polyvinyl alcohol, poly-(alkylene amines) and poly-(alkylene oxide).

Unless clearly definition is arranged in addition, otherwise " polymer " used herein and " polymeric system " comprise copolymer and blend.Polymeric system can be used such as graft copolymerization, polycondensation and addition polymerization and optionally use suitable conventional copolymerization techniques such as catalyst to prepare.With regard to time and temperature, these technology can adopt the usual manner of knowing in the polymer arts to carry out.Perhaps, polymeric system can prepare with the standard blending technology of polymer or the blend of copolymer, and for time and temperature, can adopt the usual manner of knowing in the polymer arts to carry out equally.

Polymeric system, manufacture method and medicine loaded select, make this device not form hydrogel when (for example being transplanted among the animal or human experimenter in vivo) in the water-based system contacting or be immersed into water-based system.Polymeric system is characterised in that it has the hydrophobicity of reduction with respect to pure hydrophobic polymer component owing to the adding of hydrophilic component.This helps this device to absorb water and the activating agent that helps to be added or the dissolving and the release of reagent, thereby avoids the lag period occurring and cause linearity or near the release dynamics of zero level.

The term " hydrogel " that the present invention uses is to use with the general fashion in this area, for example is meant such polymer or copolymer systems: expand under the situation that has water or other water-based system, and shrink lacking under the few situation of the water or the water yield; In its structure, can remain with the water of considerable part and water insoluble usually.It should be appreciated by those skilled in the art that a lot of routine techniquess can be used for measuring the effect whether polymer or copolymer systems play hydrogel, for example in being immersed into water-based system, form hydrogel when (as being implanted among the animal or human experimenter) by body.

For example, polymer or polymeric system can adopt the mode of shot-like particle to prepare or pulverize or make particle to form powder.In proper container described powder mixed with distilled water then and place time enough, for example about 15 minutes～24 hours or longer time are to form gel.Can use conventional optical microscope that gained solution is observed then, so that search the formation of characteristic gel suspension, and determine that in view of the above hydrogel forms, perhaps observe particle and whether can not form suspension and/or from solution, be settled out, thereby showing that this polymeric acceptor ties up to does not form hydrogel when being immersed in the water-based system.

Perhaps, except said method, can estimate polymer or the copolymer systems absorbability in water-based system, wherein the polymer water absorbing capacity is the property feature of hydrogel formation property polymer.Therefore, term used herein " absorbability " can be meant the value that records according to following method.In the absorbefacient situation of deionized water, 2 liters deionized water and the exsiccant polymer of 1g can be put into 3 liters of beakers, under agitation allow polymer absorb water about 30 minutes～24 hours or the longer time, filter with 100 purpose metal gauzes then and collect this polymer, utilize graduated cylinder to measure the volume of the expansible polymer that obtains as filter cake then.Then can be with the deionized water absorbability value of the value that records thus as polymer.Absorbability value high more (as the value up to the initial weight of polymer) shows to have formed hydrogel, and less value then shows and do not form hydrogel.

In the absorbefacient situation of saline solution, saline solution (sodium-chloride water solution of 0.9 weight %) and the exsiccant polymer of 1g of 200ml can be put into the 300ml beaker, under agitation allow polymer absorb this solution about 30 minutes～about 24 hours or the longer time, filter with 200 purpose metal gauzes then, and can utilize graduated cylinder to measure the volume of the expansible polymer that obtains as filter cake.Then can be with this value as the saline solution absorbability value of polymer.Similarly, higher value (as near or surpass the value of the initial weight of polymer) show and formed hydrogel.

Be called in the test of centrifugal hold facility test at another, can take by weighing a spot of polymer, put it in the bag of making tea, the bag of then this being made tea is sealed up.Afterwards, the bag of making tea is put in the sodium chloride solution (sodium chloride solution/1g of 1.25～1 hydrogel to be measured) more than the 0.9 weight % at least.Expanding about 20 minutes～about 24 hours or after longer time, the bag of will making tea takes out from sodium chloride solution and with 250g centrifugal for 3 times.Weigh then through the centrifugal bag of making tea to determine the amount of the liquid that hydrogel is kept.The amount of the liquid that any tangible tested compositions kept all shows the formation of hydrogel.

Except above-mentioned assessment, also have available other method of testing of a lot of those skilled in the art, can measure the ability that selected polymer or copolymer systems form hydrogel in being immersed into water-based system the time by these methods.

B. activating agent

On essence, any activating agent can use conventional method (comprising those methods described herein) and polymeric system to merge to form device of the present invention.Therefore, term used herein " activating agent " can comprise by part or whole body behavior and is applied to organism (human or animal experimenter), thereby induce any compound or the composition of matter of the material of required pharmacy and/or physiologic effect.Therefore, this term comprises those chemical compounds or the chemical substance that is considered to medicine, medicine biology (comprising such as peptide, protein and nucleic acid equimolecular) and vaccine traditionally.This term further comprises chemical compound or the chemical substance that is considered to diagnostic reagent traditionally.

Therefore, useful activating agent comprises chemical compound or the compositions (cholinergic agonist, anticholinesterase, atropine, scopolamine and relevant Antimuscarinic drugs, catecholamine, sympathomimetic and adrenergic aceptor antagonist) that acts on synapse and neural effector binding site in practice of the present invention; Act on central nervous system's medicine; Tissue hormone's (pharmacotherapy of inflammation); Influence the medicine of renal function and electrolyte metabolism; Cardiovascular drug; Influence the medicine of gastrointestinal function; The chemotherapeutic agent of neoplastic disease; Act on the medicine that blood and blood form organ; Hormone and hormone antagonist.Term used herein " medicine " comprises and is intended to be used for curing, alleviate, treat or preventing any disease, imbalance or discomfort except food, perhaps is intended to be used to influence any material of the structure or the function of body.This term can comprise biologically active or be intended in order to change any useful reagent or the material of animal physiological.Medicine can be natural or synthetic organic compound, protein, peptide, nucleic acid molecules, glycoprotein, sugar, carbohydrate, lipid or their combination.Peptide and protein are the preferred especially medicines that uses in the present composition.

More specifically, the activating agent type that can be used for the present composition includes but not limited to: such as anti-infectives such as antibiotic and antiviral agent; Analgesic and analgesic combination; Part and general anesthetic; The loss of appetite medicine; Anti-arthritic; Anti-asthmatic agent; Anticonvulsant; Antidepressants; Antihistaminic; The antibiotic medicine; Antinanseant; The migraine agent; Antitumor drug; Antipruritic; Psychosis; Antipyretic; Spasmolytic; Cardiovascular preparation (comprising calcium channel blocker, beta blocker, beta-2-agonists and anti-arrhythmic); Antihypertensive; Diuretic; Vasodilator; Central nervous system stimulant; Cough and cold-treating preparation; Decongestant; Diagnostic agent; Hormone; Bone growth stimulator and bone resorption inhibitor; Immunosuppressant; The muscular flaccidity agent; Psychostimulant; Tranquilizer; Tranquilizer; Protein, peptide and their fragment; Nucleic acid molecules (the polymerized form of two or more nucleotide, be ribonucleic acid acid (RNA) or nnucleic acid (DNA), it comprises double-stranded and single chain molecule and superhelix or concentrated molecule, gene construct, expression vector, plasmid, antisense molecule etc.).

An interesting especially class medicine that uses as activating agent in this article is anesthetis class, for example benzocaine, bupivacaine, etidocaine, lignocaine, mepivacaine, pramocaine, prilocaine, procaine, proparacaine, ropivacaine, tetracaine, chirocaine, chloroprocaine, butacaine, propoxycaine, Holocaine, hexylcaine, isobucaine, cyclomethycaine, oxybuprocaine, diperodon, cincaine, meprylcaine, quinisocaine, pramocaine, butamben, dyclonine (have or do not have) such as reinforcing agents such as dexamethasone or epinephrines.

The especially interesting another kind of medicine that uses as activating agent in this article is the opioid class; It comprises alfentanil; Allylprodine; Alphaprodine; Anileridine; Apomorphine; Apocodeine; Benzyl morphine; Bezitramide; Buprenorphine; Butorphanol; Clonitazene; Codeine; Cyclazocine; Cyclorphen; Cyprenorphine; Desomorphine; Dextromoramide; Dezocine; Diampromide; Dihydrocodeine; Dihydromorphine; Dimenoxadol; Dimepheptanol; Dimethylthiambutene; Dioxyaphetyl butyrate; Dipipanone; Eptazocine; Ethoheptazine; Ethylmethylthiambutene; Dionin; Etonitazene; Fentanyl; Heroin; Hydrocodone; The hydroxymethyl morphinan; Hydromorphone; Hydroxypethidine; Isomethadone; Ketobemidone; Levallorphan; Levorphanol; Levophenacylmorphan; Lofentanil; Pethidine; Meptazinol; Metazocine; Methadone; Methylmorphine; Metopon; Morphine; Myrophine; Nalbuphine; Narceine; Nicomorphine; Norlevorphanol; Normethadone; Nalorphine; Normorphine; Norpipanone; Ohmefentanyl; Opium; Oxycodone; Oxymorphone; Narsco; Pentazocine; Phenadoxone; Phenomorphan; Phenazocine; Phenoperidine; Pholcodine; Piminodine; Pirinitramide; Propheptazine; Promedol; Profadol; Piperazine third is sharp fixed; Propiram; The third oxygen sweet smell; Remifentanil; Sufentanil; Bent horse is many; For sharp fixed; Naltrexone; Naloxone; Nalmefene; MNTX; The naloxone methiodide; Nalorphine; Naloxonazine; Nalide; Nalmexone; Nalbuphine; Two nicotinic acid nalorphines; Naltrindol (NTI); Isothiocyanic acid naltrindol (NTII); Naltriben (NTB); Nor-binaltorphimine (nor-BNI); β-funaltrexamine (b-FNA); BNTX; Cyprodime; ICI-174; 864; LY117413; MR2266; Etorphine; DAMGO; CTOP; Diprenorphine; Naloxone benzoyl hydrazone; Bremazocine; Ethyl ketone base cyclazocine (ethylketocyclazocine); U50; 488; U69; 593; Spiradoline; DPDPE; [D-Ala2, Glu4] deltorphin; DSLET; Methionine-enkephalin; LEnK; Beta-endorphin; Dynorphin A; Dynorphin B; α-neoendorphin or have the opioid of the five rings identical with following material nuclear: nalmefene; Naltrexone; Buprenorphine; Levorphanol; Meptazinol; Pentazocine; Dezocine or they are at pharmaceutically effectively ester or salt.

The interesting especially another kind of medicine that uses as activating agent is non-steroidal anti-inflammatory medicine (" NSAID ") in this article, and it comprises salicylate, pyrazolone, indomethacin, sulindac, fragrant that ester, Tolmetin and propanoic derivatives; For example salicylic acid, aspirin, methyl salicylate, two fluorine Buddhist nun willow, salsalate, phenylbutazone, indomethacin, oxyphenbutazone, azapropazone, mefenamic acid, meclofenamate sodium, ibuprofen, naproxen, naproxen sodium, fenoprofen, ketoprofen, flurbiprofen, piroxicam, diclofenac, etodolac, ketorolac, aceclofenac, nabumetone etc.

Protein is the more preferred at present another kind of medicine that uses as activating agent in the present invention's practice.Term " protein " comprises peptide, polypeptide, total molecule and their analog, derivant or combination.Therefore this term comprises molecule reorganization or naturally occurring, and no matter this molecule comes from people or animal, this molecule comprises naturally occurring, synthetic, semisynthetic or the reorganization generation.The suitable peptide that uses in the present composition and/or the example of protein active agent comprise hormone, somatomedin, neural activity agent, Hemopoietic factor, melanotropin peptide, the cell adhesion factor, cytokine and biological response modifier, the obesity factor, trophic factors, the antiinflammatory factor, enzyme and antibody molecule.Preferred cytokine and biological response modifier comprise that interferon (for example sees United States Patent (USP) 5,372,808; 5,541,293; 4,897,471; With 4,695,623) and interleukin (for example seeing United States Patent (USP) 5,075,222).Preferred Hemopoietic factor comprises that erythropoietin (for example sees United States Patent (USP) 4,703,008; 5,441,868; 5,618,698; 5,547,933; With 5,621,080), and the preferred obesity factor comprises that OB albumen (for example sees international publication WO 96/40912; WO96/05309; WO 97/00128; WO 97/01010 and WO 97/06816).Preferred somatomedin comprises that granulocyte colony-stimulating factor (for example sees United States Patent (USP) 4,999,291; 5,581,476; 5,582,823; 4,810,643 and international publication WO 94/17185); Stem cell factor (is for example seen international publication WO 91/05795; WO 92/17505 and WO 95/17206); The basic fibroblast growth factor of cattle and people's form comprises that its analog (for example sees United States Patent (USP) 5,859,208; 5,604,293; 5,514,566; 5,439,616; 5,464,774; 5,155,214; With 4,956,455); The VEGF of cattle and people's form comprises that its analog (for example sees (1991) such as Ferrara, J.Cellular Biochem.47:211-218; Connolly (1991) J.Cellular Biochem.47:219-223; Joukov etc. (1996), EMBO J.15:290-298 and international publication WO96/26736 and WO 95/24473).

Especially the hormone that is preferably used as activating agent is gonadotropin releasing hormone (" GnRH ") and analog thereof, and this hormone is also referred to as luteinizing hormone releasing hormone (" LHRH ").GnRH regulates fertility has main effect (Johnson etc. (1988), Essential Reproduction, the 3rd edition, Blackwell Scientific Publications).Male and female in, GnRH from hypothalamus be discharged into the blood flow and by blood transport to hypophysis, induce gonadotroph to discharge promoting sexual gland hormone, luteotropic hormone (" LH ") and follicle stimulating hormone (" FSH ") this its, and regulate androgen, estrogen and progestogen.

Term used herein " GnRH analog " is intended to comprise the peptide compounds of the structure of simulating the luteotropic hormone releasing hormone.The GnRH analog can be GnRH agonist or GnRH antagonist.

" GnRH agonist " used herein thus mean and stimulate the GnRH receptor to stimulate the chemical compound of the release of luteotropic hormone and/or FSH.The example of GnRH agonist comprises leuproside, and (commodity are by name: Lupron , Abbott/TAP; Viadur , Alza), (commodity are by name: Zoladex  for goserelin; Zeneca), buserelin (Hoechst), triptorelin (are also referred to as Decapepthl, D-Trp-6-LHRH and Debiopharm.RTM.; Ipsen/Beaufour), (commodity are called Synarel  to nafarelin; Syntex), lutrelin (Wyeth), cystorelin (Hoechst), gonadorelin (Ayerst) and Supprelin (Ortho), luteinizing hormone releasing hormone, Suo Ruilin, avorelin, cetrrelix, Teverelix, ramorelix, ganirelix, safe and sound, Ni Ketaide (nictide) and sulfasalazine.In compositions of the present invention, especially preferably use the leuproside agonist.

Term used herein " GnRH antagonist " thus mean and suppress the chemical compound that the GnRH receptor suppresses the release of luteotropic hormone or FSH.The example of GnRH antagonist comprises safe and sound (Antide), cetrorelix, ganirelix and the United States Patent (USP) 5,470,947 of getting; 5,413,990; 5,371,070; 5,300,492; 5,296,468; 5,171,835; 5,003,011; 4,992,421; 4,851,385; 4,801,577; 4,689,396; With 4,431,635 and international publication WO 89/01944 described in chemical compound.

In addition; include but not limited in other protein active agent used herein: the product that obesity is relevant; insulin; gastrin; prolactin antagonist; thyroliberin (ACTH); thyrotropin (TSH); luteotropic hormone (LH); follicle stimulating hormone (FSH); human chorionic gonadotropin (HCG); motilin; interferon (α; β; γ); interleukin (IL-1 to IL-12); tumor necrosis factor (TNF); tumor necrosis factor binding protein (TNF-bp); neurotrophic factor derived from brain (BDNF); neuroglia derived neurotrophic factor (GDNF); neurotrophic factor 3 (NT3); fibroblast growth factor (FGF); neurotrophic growth factor (NGF); skeletal growth factor (for example osteoprotegerin (OPG)); insulin like growth factor (IGF); M-CSF (M-CSF); granulocyte macrophage colony stimulating factor (GM-CSF); huge keratinocyte (megakeratinocyte) derivative growth factor (MGDF); thrombopoietin; platelet derived growth factor (PGDF); colony-stimulating somatomedin (CSF); bone morphogenetic protein (BMP); superoxide dismutase (SOD); tissue plasminogen activator (TPA); urokinase; streptokinase; kallikrein; such as blood factors such as Factor IX and factors IX, and polyclonal antibody; monoclonal antibody; chimeric antibody molecule and antibody fragment.

In those devices that are intended to as vaccine, activating agent can be an antigen, that is, contain one or more can stimulation of host immune systems produce the molecule of the epi-position that cellular antigens specific immune responses and/or humoral antibody reply.Therefore, suitable antigen comprises protein, polypeptide, antigenic protein fragment, oligosaccharide and polysaccharide etc.Antigen can also can be whole organism (active, that separate, attenuation or deactivation) or its immunogenicity part (for example cell-wall component) from any known virus, antibacterial, parasite, plant, protozoacide or fungus etc.Antigen can also be from tumor.The oligonucleotide of antigen expressed or polynucleotide (for example in dna immunization is used) also can be included in the antigenic definition.Synthetic antigen also can be included in the antigenic definition, for example antigen (Bergmann etc. (1993), the Eur.J.Immunol.23:2777-2781 in hapten, multi-epitope, flank epi-position and other recombinant or recombinant or synthetic source; Bergmann etc. (1996), J.Immunol.157:3242-3249; Suhrbier, A. (1997), Immunol.And Cell Biol.75:402-408; Gardner etc. (1998), 12 ^ThWorld AIDS Conference, Geneva, Switzerland's (on July 3rd, 1 1998 on June 28th, 1998)).

C. additive, excipient and hole form agent

Activating agent can with one or more such as combination of components in addition such as the acceptable excipient material of pharmacy, described excipient material can play effects such as dispersant, bulking agent (bulking agent), binding agent, carrier, stabilizing agent, fluidizer, antioxidant, pH regulator agent or counter-stimulus.It should be appreciated by those skilled in the art that some excipient material can have above-mentioned multiple function in the specific formulation arbitrarily.Therefore, the appropriate excipients material of any amount can mix with device or join in the device with bulk character be provided, change the activating agent rate of release, promotion or suppress water and absorb, control pH, structural support is provided, helps oneself other purposes of knowing of manufacture process and those skilled in the art.Term " excipient " typically refers to and is essentially inert material, and it is atoxic and does not interact in deleterious mode with other component of installing.The ratio of particular excipient in device depends on the character of purpose that this excipient is provided and this excipient.

For example, can also comprise other glucose of pharmacy level, sucrose, lactose, trehalose, mannitol, sorbitol, inositol and glucosan etc. to the appropriate carriers excipient that peptide plays stabilizer function.Therefore described carrier can be such as saccharides such as monosaccharide, disaccharide, polysaccharide or sugar alcohols.Other appropriate carriers comprises starch, cellulose, sodium phosphate or calcium phosphate, calcium sulfate, citric acid, tartaric acid, glycine and their combination.The example that can add in the device with the hydrophobic vehicle of slowing down hydration and dissolution kinetics comprises fatty acid and the acceptable salt of its pharmacy (for example magnesium stearate, stearic acid, zinc stearate, palimitic acid and sodium palitate).

In device of the present invention, can also adopt charged lipid and/or detergent excipient.Suitable charged lipids includes but not limited to phosphatidylcholine (lecithin) etc.Detergent is generally non-ionic surface active agent, anion surfactant, cationic surfactant or amphoteric surfactant.The example of suitable surfactant comprises for example Tergitol  and Triton  surfactant (UnionCarbide Chemicals and Plastics); Polyoxyethylene sorbitan, for example TWEEN  surfactant (Atlas Chemical Industries); Polysorbate; Polyoxyethylene ether, for example Brij; The acceptable fatty acid ester of pharmacy, for example lauryl sulfate or its salt; Amphoteric surfactant (glyceride etc.); And other similar substance.

Other excipient material can add in the device to change porosity, for example sucrose, glucose, sodium chloride, sorbitol, lactose, Polyethylene Glycol, mannitol, fructose, polyvinylpyrrolidone or their suitable materials such as combination.In addition, activating agent can be with oil (for example Oleum sesami, Semen Maydis oil and vegetable oil), or the mixture or the MCT Oil (for example Miglyol 812) of itself and phospholipid (for example lecithin) are disperseed so that oily suspensions to be provided.

Can add the diluent that other excipient material in the device of the present invention comprises various buffering content (for example Tris-HCl, acetate) to; PH and ionic strength change agent; Such as antioxidant additives such as (for example ascorbic acid, glutathion, sodium metabisulfites); Antiseptic (for example Thimersol, benzyl alcohol, methyl parahydroxybenzoate and propyl p-hydroxybenzoate); And such as water soluble polysaccharide (for example, mannitol, lactose, Fructus Vitis viniferae sugar and starch), hyaluronic acid, glycine, fibrin, collagen and inorganic salt dispersants such as (for example sodium chloride).

D. install

Polymeric device of the present invention on ordinary meaning by the combination of activating agent and polymeric system is formed, described polymeric system has hydrophobic components and hydrophilic component, wherein this device supplies the usefulness of sustained release activating agent under proper condition, and has as whole description physical property described in detail.Therefore, term used herein " device " is meant the polymeric device that is used for the sustained release active agent of interest.This device comprises as having the copolymer of hydrophobic components and hydrophilic component or a biodegradability polymeric system of polymer blend, and wherein said polymeric acceptor ties up to that (for example when being implanted to this device among the experimenter alive) do not form hydrogel when contacting or being immersed in the water-based system with water-based system.Activating agent is joined in the polymeric system, make that this polymeric system can be for the usefulness of the described reagent of sustained release from described device.Optionally, can add one or more excipient materials in this polymeric system absorbs, controls pH, structural support is provided, helps manufacture process or similar applications with the water that bulk character is provided, changes rate of release, promotion or the restraining device of activating agent.When this device is applied to the experimenter when this device (for example when implant), this device discharges described activating agent in a controlled manner and does not have the lag period or have the shortest lag period.

In the structure of apparatus of the present invention, described polymeric acceptor ties up to hydrophobic polymer component and hydrophilic polymer or monomer copolymerization to obtain suitable copolymer systems, make when most preferably being block copolymer, perhaps hydrophobic polymer component and hydrophilic polymer blend are being made when obtaining suitable blending polymeric system.Polymeric system can be used such as graft copolymerization, polycondensation and addition polymerization and optionally use suitable conventional copolymerization techniques such as catalyst to prepare.With regard to time and temperature, these technology can adopt usual manner to carry out.Perhaps, polymeric system can prepare with the standard blending technology of polymer or the blend of copolymer, and is same for the time and temperature of this method, can adopt usual manner to carry out.

In described polymeric system itself, hydrophobic components and hydrophilic component can exist with any proper proportion, wherein the concrete content of each component is selected according to the hydrophobicity or the hydrophilic relative extent of each component respectively, but always makes final device product not form hydrogel contact or be immersed in the water-based system with water-based system after.Therefore, being characterized as of the polymeric system of gained: have a spot of water-wet behavior, but with respect to hydrophobic components, the amount of hydrophilic component in polymeric system is relatively low usually, thereby applicator hydrogel character not, but still form the device that shows the single-phase or zero level of activating agent or approach the zero level release dynamics.Therefore, the amount of hydrophilic component in polymeric system is about 25 weight %～30 weight % usually or still less, in some cases, this amount approximates or is lower than 15 weight %, and in some other situations, this amount is about 0.5 weight %～10 weight %.

Some preferred embodiment in, polymeric acceptor is copolymer or the polymer blend that comprises the hydrophobic polymer component that surpasses about 75 weight %.In other preferred implementation, polymeric acceptor is copolymer or the polymer blend that comprises the hydrophobic polymer component that surpasses about 85 weight %, in other other embodiment, polymeric acceptor is to comprise to surpass copolymer or the polymer blend of about 91 weight % to the hydrophobic polymer component of about 98 weight %.In a specific embodiment, the hydrophobic components in the polymeric system is a polyhydroxy acid, for example gathers (lactide), gathers (Acetic acid, hydroxy-, bimol. cyclic ester), gathers (lactide-co-glycolide), gathers (lactic acid), gathers (glycolic) and gathers (lactic acid-be total to-glycolic); Polyanhydride; Poe; Polyether ester; Polycaprolactone; Polyesteramide; Poly-phosphazine; Merlon; Polyamide or their any copolymer.In a particularly preferred embodiment, the hydrophobic components of polymeric system is that the amount in described system is poly-(lactide-co-glycolide) that is equal to or greater than 90 weight %.

In some other preferred implementation, polymeric acceptor is copolymer or the polymer blend that comprises less than the hydrophilic polymer component of about 25 weight %.In other preferred implementation, polymeric acceptor is copolymer or the polymer blend that comprises less than the hydrophilic polymer component of about 10 weight %, in a specific embodiment, the hydrophilic component in the polymeric system is poly-(aklylene glycol), polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVOH), poly-(alkylene amines), poly-(alkylene oxide) or their any copolymer.One preferred embodiment in, the hydrophilic component in the polymeric system is Polyethylene Glycol (PEG), and in another embodiment, described hydrophilic component is that molecular weight is the PEG of about 700Da～about 500kDa.In a particularly preferred embodiment, described hydrophilic component is the PEG that is equal to or less than 10 weight % for the amount in described polymeric system.

In a concrete embodiment, polymeric system is to be the AB block copolymer that 750 PEG forms by poly-(DL-lactide-co-glycolide) and molecular weight, and wherein the amount of PEG in polymeric system is about 1.25 weight %.

In case selected suitable polymeric system, combined polymerization step or polyblend step can be carried out before joining activating agent in the polymeric system or when adding.Therefore can activating agent and polymeric system be made up to form described device with routine techniques.The compound mode that activating agent adopts makes that its amount in device of the present invention is about 0.1 weight %～about 80 weight % or higher, but the amount of activating agent is generally about 0.3 weight %～about 70 weight %, for example about 10 weight %～about 60 weight % or about 20 weight %～about 55 weight %.Actual content depends on the activity of activating agent, required dosage, required release duration, frequency of administration and other variable.Those skilled in the art are by therapeutics, pharmacy or the diagnostics's effect used and observation post needs, should be able to determine the effective dose of the activating agent selected for use.Therefore, the definite content of activating agent in device should be that activating agent obtains the required content of valid density in vivo in the given time.This content changes with the type of used activating agent, required release duration, targeting condition, required frequency of administration, the kind of animal and the variation of other factors under test.Preferably, described device should contain the activating agent of capacity, makes the release of about 0.10 μ tg/kg/ days～100mg/kg/ days can obtain required effect.Should be to understand easily these parameters those of ordinary skills after reading this description.

According to being used for thereby activating agent is added to the technology that forms device of the present invention in the polymeric system, activating agent can be evenly distributed in the polymeric system, perhaps can be aggregated objects system basically and seal.Can further activating agent be joined in the polymeric system with suitable aqueous or nonaqueous dicyandiamide solution, perhaps can add described reagent with non-solvent processes.

Except being added to activating agent in the polymeric system, this device can further comprise uses the acceptable excipient of required pharmacy such as diluent, antiseptic, solubilizing agent, emulsifying agent and/or carrier.The ratio of existing particular excipient depends on the purpose that excipient is provided and the characteristic of this excipient in the device.The final pharmaceutical formulations of the best of active agent of interest will be decided according to route of administration and required dosage by those skilled in the art.The example of pharmaceutical compositions be disclosed in Remington ' s Pharmaceutical Sciences (1990, Mack Publishing Co., the 18th edition, Easton, Pa.) in.

In a specific embodiment of the present invention, above-mentioned polymeric system is used to make one or more polymeric devices, and this device is used for the sustained release activating agent, is used for the treatment of or alleviates the situation that this activating agent will be treated.Therefore, in one aspect of the invention, the biodegradability polymeric system is used in the manufacturing of polymeric device of sustained release activating agent, wherein polymeric acceptor is copolymer or the polymer blend that comprises hydrophobic components and hydrophilic component, and this polymeric acceptor ties up to contact or be immersed into water-based system and do not form hydrogel when (for example this device being implanted among the experimenter alive) in the water-based system.Activating agent is joined in the polymeric system, make polymeric system supply the usefulness of this reagent of sustained release from described device.When described device was applied to the experimenter, for example, when implanting described device, this device discharged described activating agent in a controlled manner and does not have the lag period or have the shortest lag period.One preferred embodiment in, use polymeric system manufacturing of the present invention to be used for the polymeric device of sustained release peptide or protein active agent.In a particularly preferred embodiment, be used for the polymeric device of sustained release GnRH activating agent or its analog with polymeric system manufacturing.

Device of the present invention can provide with any suitable form, and this depends on and will use the mode of this device.To this, device of the present invention can be used in the following manner: oral route (for example, such as capsules such as hard capsule and soft capsules, such as granule, tablet, pill, lozenge or lozenge, cachet, pilule, powder, granule, microgranule solid preparations such as (and other particulate form)); With non-oral route (for example, in intramuscular, subcutaneous, transdermal, internal organs, IV (intravenous), IP (intraperitoneal), intra-arterial, the film sheath, in the capsule, in the eye socket, in ophthalmic, the tumor, around the blood vessel, intracranial, near the eyes, in the eyelid, in the intranasal, hole, in the intravesical, intravaginal, urethra, internal rectum, adventitia, injectable, pulmonary, can suck, see through mucosa with other suitable form).One preferred embodiment in, device is used by implantation, thereby be configured to, or comprise suitable any other geometry of microgranule, microsphere and/or microcapsule such as moulded products such as spherical, rod shape, tabular, membranaceous, fibrous, needle-like, cylindric, lamellar, tubuloses.Can provide described device to be used for privileged sites, for example as conduit with the appropriate size and the shape of implantable device, diverter, the device that is used for continous pouring under the arachnoidea, feeding tube, prevent the solid implant of surgical adhesions, the uterus implant, artificial sphincter, the all implants of urethra, clamping plate, ocular implants, contact lens, the plasticity surgery implant, comprise esophageal stents appear, gastrointestinal tract support, intravascular stent, biliary tract rack, the colon support, the pancreas support, ureter bracket, urethra rack, lacrimal stent, the pharyngotympanic tube support, method Lou skin Europe support, nose stretcher, the hole support, support such as trachea bracket or bronchial stent (contain or be coated with activating agent) or comprise the venous access device, the property implanted passage, epidural catheter or centre pipe passages such as (PICC).Described device can or use trocar, conduit etc. to be implanted to desired area by the technology of invasive minimum by operation.This implant can be used such as routine techniquess such as (for example in intra-arterial, intravenous, intravaginal, internal rectum or the periodontal cavity) implantation in Intradermal, subcutaneous, percutaneous, intraperitoneal, intramuscular or the tube chamber and be implanted in any suitable tissue.Perhaps, described device can be made the part of substrate, graft, prosthesis or coating.If implanting device is made into such as microgranule, microsphere or microcapsule equigranular thing form, then can use apparatuses such as sleeve pipe, pin and syringe to inject the suspension of described shot-like particle and it is implanted in the suitable tissue.

II. manufacture method

Manufacturing is used for the method for the fibrous polymeric device of delivery of active agents and knows in this area.For example see Cowsar and Dunn, the 12nd chapter " Biodegradable andNonbiodegradable Delivery System " 145-162 page or leaf; Gibson etc., the 31st chapter " Development of a Fibrous IUD Delivery System forEstradiol/Progesterone " 215-226 page or leaf; " Fibrous Polymers for theDelivery of Contraceptive Steroids to the Female Reproductive Tract " 125-146 page or leaf of Dunn etc.; Dunn etc. (1985) " Fibrous Delivery Systems for AntimicrobialAgents " (comes from Polymeric Materials in Medication, C.G.Gebelein and Carraher edit, Plenum Publishing Corporation, the 47-59 page or leaf).Any of these known method and other several different methods known in the art may be used in the practice of the present invention, so that make the fibrous device with peculiar property described herein.

In Chris Rauwendaal (1994) " Polymer Extusion " (the 3rd revised edition, Carl Hanser Vertag, Munich) describing in has the whole bag of tricks of handling polymer by extruding, for example plasticate and extrude, wherein polymer is installed in the extruder as solid, extrude with the fusion charging, wherein the polymer with fusing installs in the extruder.Term used herein " is extruded " or " melt-spun " comprises all these manufacture methods.In melt-spun, thermoplastic polymer is heated to more than its fusing point, extrude by the hole, and cooling forms filament.In a preferred implementation making device of the present invention, before extruding,, grind this mixture then to be formed for weighing the feed of extrusioning mixture to guarantee uniform mixing with peptide activating agent and polymer mixed.Though usually formed is that the cross section is circular geometry, described device also can be made with any other cross-sectional geometry, for example oval, leaf, square or triangle.Polymer also can be made microgranule, lamellar, membranaceous or coating with conventional process technology.

Described device can be made various sizes, and this depends on the accumulated dose of medicine and application process and the site of administration of being envisioned.One preferred embodiment in, described device is that overall diameter is the monoblock type rod of 0.05mm～5.0mm.For people's subcutaneous administration, may preferred overall diameter be 1.0mm～4.0mm.The length of described device is generally about 0.3cm～10cm.For subcutaneous implantation, more preferably length is about 0.3cm～3.0cm.

Can described material is hot candied by realizing along two groups or more godet, described godet further moves with the speed of accelerating gradually along link tester is out-of-date at material.Described material can accurately be controlled the degree of crystallinity of its temperature with impact polymer thus by the heating furnace between the godet.The hot candied final diameter that also can be used for control material.

Because this structure is to be made by continuous extrusion molding, so they can provide the random length of being convenient to operate.If preparation has enough pliabilities, then can with its on spool or coiled volume and be saved to cut-out by this way before.Perhaps, this material can be with short length (may be several centimetres or several meters) collection and before being saved to cut-out.Also can when the described material of preparation, described material be cut into resulting device length with the profile type cutting machine that just places the downstream that is close to mould.

The addition of activating agent and the consumption in the method can according to specific reagent, activating agent in the required effect of designed emission levels and the time span during should discharging this reagent change.Said method can be used for more than a kind of activating agent is joined in the described polymeric device arbitrarily.

III. using method

Device constructed in accordance can be used with suitable method.According to the activating agent of being used, selected form (size, shape etc.) and selected site of administration, can carry or implant this device at the position that will discharge with the method for invasive minimum.These methods can comprise with trocar or conduit implants, places (for example substrate, graft, prosthesis or coating are used), sucks (for example powder or shot-like particle are used) etc. with conventional pin and syringe (for example powder, particle, microgranule, microsphere and microcapsules) injection, grafting or operation or non-operation.Described device can be designed so that activating agent discharges with required dosage in the time of determining.Described device can also be designed so that this device in the activating agent dispose procedure or finish discharge after degraded.

One preferred embodiment in, described device can be mixed with and comprise GnRH molecule or GnRH analog in the solid implant form.Then described device is applied to the experimenter so that target blood levels, output, function or the activity of promoting sexual gland hormone LH or FSH be similar to appear at or approach the experimenter when having maximum fertility (this is equivalent to 18 years old～35 years old in the middle of the mankind) such.For example, the normal blood level of Ci Shi LH is about 0～10.0mIU/mL (male) and about 0.4mIU/mL～92.9mIU/mL (women) (this level fluctuates with reproductive cycle).The normal blood level of the FSH of this moment is about 2.0mIU/mL～22.6mIU/mL (male) and about 2.9mIU/mL～29.5mIU/mL (women) (this level is also with the reproductive cycle fluctuation).The blood levels that the using of GnRH or GnRH analog implant is suitable for changing promoting sexual gland hormone LH or FSH, output, function or active to reach required level.

In another embodiment, described device can be mixed with and comprise GnRH molecule or GnRH analog in the solid implant form.Then described device is applied to the experimenter, so that the target blood levels of LH or FSH, output, function or the active level that can't detect or almost can't detect that reaches.For example, in clinical laboratory, the LH of 0.7mIU/mL and FSH can't detect at present.

In yet another embodiment of the present invention, described device can be mixed with and comprise GnRH molecule or GnRH analog in the solid implant form.Then described device is applied to the experimenter, does not have unacceptable adverse side effect so that target blood levels, output, function or the activity of LH or FSH are low as much as possible.Described unacceptable adverse side effect is the reasonable judgement according to those of ordinary skills, has surpassed the adverse side effect of treatment benefit.

In the practice of these methods and other method, can periodically monitor blood levels, output, function or the activity of experimenter's LH or FSH, and can titrimetry or change combination, amount and the dosage of LH/FSH inhibitor, so that LH and FSH reach target blood levels, target output, objective function or targeted activity.In a particularly preferred embodiment, the dosage of GnRH analog (for example acetic acid leuproside) can be conspicuous other scheme according to this description perhaps for about 0.01mcg/kg/ hour～about 100mg/kg/ days to those skilled in the art.In these methods, the experimenter begins to use lower dosage, for example about 0.01mcg/kg/ hour.After about two weeks, can measure the blood levels of LH and FSH.If the blood levels of LH and FSH still surpasses target level, then can increase dosage (for example increasing 0.1mcg/kg/ hour).This titrimetry can repeat, up to blood levels, output, function or active required target blood levels, output, function or the activity that provides as above that reach of LH or FSH.

For example, can use the acetic acid leuproside that the 30mg time discharges dosage to the bull experimenter.Acetic acid leuproside activating agent can be provided in the polymeric system of biodegradability, so that the polymeric device in order to this activating agent of sustained release to be provided.Polymeric acceptor is copolymer or the polymer blend that comprises hydrophobic components and hydrophilic component, and this polymeric acceptor ties up to, and (for example when being implanted to this device among the experimenter) do not form hydrogel when contacting or being immersed in the water-based system with water-based system.Acetic acid leuproside activating agent is joined in the polymeric system, make polymeric system for usefulness from this reagent of device sustained release.When described device is applied to the experimenter (for example, when implanting described device), this device discharges described activating agent in a controlled manner and does not have the lag period or have the shortest lag period.In this mode, leuproside can discharge in the several months gradually.After two weeks, possibly can't detect experimenter's LH blood levels, and experimenter's FSH blood levels may be about 5mIU/mL.

In another embodiment, can use the acetic acid leuproside that the 1.88mg time discharges dosage to the experimenter.Acetic acid leuproside activating agent can be provided in the polymeric system of biodegradability, so that the polymeric device in order to this activating agent of sustained release to be provided.Polymeric acceptor is copolymer or the polymer blend that comprises hydrophobic components and hydrophilic component, and this polymeric acceptor ties up to, and (when for example being implanted to this device among the experimenter) do not form hydrogel when contacting or being immersed in the water-based system with water-based system.Acetic acid leuproside activating agent is joined in the polymeric system, make polymeric system supply the usefulness of this reagent of sustained release from device.When described device is applied to the experimenter (for example, when implanting described device), this device discharges described activating agent in a controlled manner and does not have the lag period or have the shortest lag period.In this mode, leuproside can be in about 1 month discharges gradually, and the LH among the expection experimenter and the blood levels of FSH can be reduced to the level that can't detect.To those skilled in the art, according to this description, it is evident that in order to reach this target, the dosage of leuproside activating agent can be according to following factor, change to some extent between different experimenters, described factor is the process of age, sex, body weight, diet, the disease for the treatment of, this disease and the other medicines of using for example.

Below be the embodiment that implements the specific embodiment of the present invention.Providing these embodiment only for illustration purpose, is not to be intended to scope of the present invention is carried out any qualification.

Embodiment 1: poly-(DL-lactide-co-glycolide) PEG block copolymer implant

Method

Prepare poly-(DL-lactide-co-glycolide) PEG block copolymer of 90: 10: the molecular weight that utilizes 8.3 weight % is that end capped poly-(ethylene glycol) [mPEG-5000] of mono methoxy of 5,000 prepares at 30 ℃ in CHCl as initiator and DL-lactide-co-glycolide ₃In intrinsic viscosity be the block copolymer of 0.89dL/g.The copolymer that melt extrudes gained then serves as the rod of about 1.5mm with the preparation diameter, and described rod is cut into the device of length for about 2cm.Then this device is put into the scintillation vial of the S  renson phosphate buffer of the clean 67mM that 10mL is housed.With this sample preservation in 37 ℃ incubator.After the contacting of 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 14 weeks and 16 weeks, carried out the exchange fully of buffer.During above-mentioned each sample, from this research, take out 3 devices, and write down its weight in wet base.Dry this device (ambient pressure and RT (relative humidity) carry out vacuum drying being lower than 18mm Hg then), and dry weight of each device of record.

The result

The water of polymer absorbs as shown in Figure 1.This result shows that the diameter of device is big more, and the water of its absorption is just many more.

Embodiment 2: the release characteristics that contains the implant of acetic acid leuproside

Material

9 parts are crushed to 90: 10 poly-(the DL-lactide-co-glycolide) that acetic acid leuproside that mean diameter is 3 μ m～10 μ m and 27 parts of mPEG 750 cause [mPEG-750/ (90: 10DL-PLG)] combination and fully mix; Described mPEG-750/ (90: 10 DL-PLG) is at CHCl ₃In intrinsic viscosity be 0.89dL/g, mPEG content is 1.25 weight %, and has ground with the sieve by 1mm.Then 80 ℃～120 ℃ temperature on the screw extruder of 0.375 inch diameter by melt extruding the preparation powder blend.Grind this extrudate, and on identical device with identical temperature range heavily extrude with the preparation diameter serve as the rod of about 1.5mm.Then, cutting described rod serves as the device of about 2cm to form length.

By the following method this device is carried out testing in vitro: single assembly is put into the S  rensen phosphate buffer (pH7.4) that contains 0.05 weight % Hydrazoic acid,sodium salt of the 67mM of 10mL, and 37 ℃ of cultivations.Regularly change described buffer, and analyze old buffer, to measure the amount of the leuproside that from this implant, has discharged with fresh buffer.

The result

Release from device shown in Figure 2 shows that in about 7 days time, leuproside has carried out burst release, is comparatively slowly stable release then.

Embodiment 3: the release characteristics that contains the implant of acetic acid leuproside

With IV=0.89dL/g and contain the mPEG-5000/ (90: 10DL-PLG) repeat the experiment of embodiment 2 of the mPEG of 8.3 weight %.As shown in Figure 3, observe similar release profiles.

Improvement of the present invention and change are significantly to those skilled in the art, and comprise within the scope of the appended claims.

Claims (56)

1. the polymeric device that is used for the sustained release active agent of interest, described device comprises:

The biodegradability polymeric system, this biodegradability polymeric system is selected from copolymer and the polymer blend that contains hydrophobic components and hydrophilic component; With

Activating agent, wherein said polymeric acceptor tie up to when described device contacts with water-based system and do not form hydrogel, and wherein said device does not have the lag period when discharging described reagent or has the shortest lag period.

2. device as claimed in claim 1, the amount of wherein said reagent are at most 40 weight %.

3. device as claimed in claim 1 or 2, wherein said activating agent are peptide.

4. device as claimed in claim 3, wherein said peptide are therapeutic and/or the preventative peptide that is selected from following material: hormone, somatomedin, neural activity agent, melanotropin peptide, the cell adhesion factor, cytokine and biological response modifier.

5. device as claimed in claim 4, wherein said peptide are gonadotropin releasing hormone molecule or gonadotropin releasing hormone analogues.

6. device as claimed in claim 5, wherein said gonadotropin releasing hormone analogues are selected from ground Suo Ruilin, color ammonia Rayleigh, goserelin and leuproside.

7. as each described device of claim 1～6, wherein said polymeric acceptor is the copolymer that contains hydrophobic components and hydrophilic component.

8. as each described device of claim 1～6, wherein said polymeric acceptor is the blend of hydrophobic polymer and hydrophilic polymer.

9. as each described device of claim 1～8, the amount of wherein said hydrophilic component is at most 25%.

10. as each described device of claim 1～8, the amount of wherein said hydrophilic component is at most 15%.

11. as each described device of claim 1～8, the amount of wherein said hydrophilic component is 0.5 weight %～10 weight %.

12. as each described device of claim 1～11, wherein said polymeric acceptor is the AB copolymer, wherein the A component is the copolymer of lactide, Acetic acid, hydroxy-, bimol. cyclic ester or caprolactone, and the B component is a poly alkylene glycol.

13. device as claimed in claim 12, wherein said B component are the poly alkylene glycol of 1.25 weight %, and hydrophobic polymer is poly-(lactide-co-glycolide).

14. as each described device of claim 1～13, wherein said activating agent is evenly distributed in the described polymer.

15. as each described device of claim 1～14, wherein said activating agent adds with non-solvent method.

16. as each described device of claim 1～15, wherein said device melt extrudes by dry type and forms.

17. as each described device of claim 1～15, wherein said device forms by melt extruding with the blended copolymer of peptide.

18. as each described device of claim 1～17, wherein said activating agent discharges with release dynamics linear or that approach zero level.

19. as each described device of claim 1～18, wherein said polymeric system comprises the hydrophobic polymer that surpasses 75 weight %.

20. device as claimed in claim 19, wherein said polymeric system comprise the hydrophobic polymer that surpasses 85 weight %.

21. device as claimed in claim 20, wherein said polymeric system comprise the hydrophobic polymer that surpasses 91 weight %.

22. device as claimed in claim 21, wherein said polymeric system comprise the hydrophobic polymer that surpasses 98 weight %.

23. as each described device of claim 1～22, the hydrophobic components of wherein said polymeric system is selected from polyhydroxy acid, for example gathers (lactide), gathers (Acetic acid, hydroxy-, bimol. cyclic ester), gathers (lactide-co-glycolide), gathers (lactic acid), gathers (glycolic) and gathers (lactic acid-be total to-glycolic); Polyanhydride; Poe; Polyether ester; Polycaprolactone; Polyesteramide; Poly-phosphazine; Merlon; Polyamide; And their copolymer.

24. as each described device of claim 1～23, the hydrophilic component of wherein said polymeric system is a Polyethylene Glycol.

25. as each described device of claim 1～24, this device provides with the form of fibrous, needle-like or rod shape.

26. as each described device of claim 1～24, this device provides with lamellar, form membranaceous or coating.

27. as each described device of claim 1～24, this device provides with particulate form.

28. as each described device of claim 1～27, this device does not contain solvent residues.

29. device as claimed in claim 1, this device is used for the treatment of disease, and wherein said activating agent is gonadotropin releasing hormone molecule or gonadotropin releasing hormone analogues.

30. device as claimed in claim 1, wherein said activating agent are gonadotropin releasing hormone molecule or the gonadotropin releasing hormone analogues that is used to reduce the promoting sexual gland hormone level.

31. make method as each described device of claim 1～30, described method comprises mixes described polymeric system with described activating agent, extrude the mixture of described polymeric system and described activating agent, grind or pulverize the mixture of being extruded, and will be provided in the extruder through the extrusioning mixture that grinds or pulverize.

32. the biodegradability polymeric acceptor ties up to the purposes of making the polymeric device that is used for the sustained release active agent of interest, wherein said biodegradability polymeric system is selected from copolymer and the polymer blend that comprises hydrophobic components and hydrophilic component, and with the combination of described activating agent to form described device, this polymeric acceptor ties up to when described device contacts with water-based system and does not form hydrogel, and wherein said device does not have the lag period when discharging described reagent or has the shortest lag period.

33. purposes as claimed in claim 32, the amount of wherein said reagent are at most 40 weight %.

34. as claim 32 or 33 described purposes, wherein said activating agent is a peptide.

35. purposes as claimed in claim 34, wherein said peptide are therapeutic and/or the preventative peptide that is selected from following material: hormone, somatomedin, neural activity agent, melanotropin peptide, the cell adhesion factor, cytokine and biological response modifier.

36. purposes as claimed in claim 35, wherein said peptide are gonadotropin releasing hormone molecule or gonadotropin releasing hormone analogues.

37. purposes as claimed in claim 36, wherein said gonadotropin releasing hormone analogues are selected from ground Suo Ruilin, color ammonia Rayleigh, goserelin and leuproside.

38. as each described purposes of claim 32～37, wherein said polymeric acceptor is the copolymer that contains hydrophobic components and hydrophilic component.

39. as each described purposes of claim 32～37, wherein said polymeric acceptor is the blend of hydrophobic polymer and hydrophilic polymer.

40. as each described purposes of claim 32～39, the amount of wherein said hydrophilic component is at most 25%.

41. as each described purposes of claim 32～39, the amount of wherein said hydrophilic component is at most 15%.

42. as each described purposes of claim 32～39, the amount of wherein said hydrophilic component is 0.5 weight %～10 weight %.

43. as each described purposes of claim 32～42, wherein said polymeric acceptor is the AB copolymer, wherein the A component is the copolymer of lactide, Acetic acid, hydroxy-, bimol. cyclic ester or caprolactone, and the B component is a poly alkylene glycol.

44. purposes as claimed in claim 43, wherein said B component are the poly alkylene glycol of 1.25 weight %, and hydrophobic polymer is poly-(lactide-co-glycolide).

45. as each described purposes of claim 32～44, wherein said activating agent is evenly distributed in the described polymer.

46. as each described purposes of claim 32～45, wherein said activating agent discharges with release dynamics linear or that approach zero level.

47. as each described purposes of claim 32～46, wherein said polymeric system comprises the hydrophobic polymer that surpasses 75 weight %.

48. as each described purposes of claim 32～46, wherein said polymeric system comprises the hydrophobic polymer that surpasses 85 weight %.

49. purposes as claimed in claim 48, wherein said polymeric system comprise the hydrophobic polymer that surpasses 91 weight %.

50. purposes as claimed in claim 49, wherein said polymeric system comprise the hydrophobic polymer that surpasses 98 weight %.

51. as each described purposes of claim 32～50, the hydrophobic components of wherein said polymeric system is selected from polyhydroxy acid, for example gathers (lactide), gathers (Acetic acid, hydroxy-, bimol. cyclic ester), gathers (lactide-co-glycolide), gathers (lactic acid), gathers (glycolic) and gathers (lactic acid-be total to-glycolic); Polyanhydride; Poe; Polyether ester; Polycaprolactone; Polyesteramide; Poly-phosphazine; Merlon; Polyamide; And their copolymer.

52. as each described purposes of claim 32～51, the hydrophilic component of wherein said polymeric system is a Polyethylene Glycol.

53. as each described purposes of claim 32～52, wherein said device provides with the form of fibrous, needle-like or rod shape.

54. as each described purposes of claim 32～52, wherein said device provides with lamellar, form membranaceous or coating.

55. as each described purposes of claim 32～52, wherein said device provides with particulate form.

56. as each described purposes of claim 32～55, wherein said device does not contain solvent residues.

Images